Share ownership Jiangsu Hengrui Pharmaceuticals Co.,Ltd

600276

CNE0000014W7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 12/02/2026			5-day change	1st Jan Change
58.74 ^CNY	-0.27%		+1.00%	-1.39%

02-11	Jiangsu Hengrui Medicine Gets Priority Review Approval for Colorectal Cancer Drug	MT
02-10	Kailera Therapeutics & Hengrui Pharma report positive topline data from phase 2 obesity trial of oral ribupatide	RE

Share class: Jiangsu Hengrui Pharmaceuticals Co.,Ltd

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,379,002,274	3,341,548,954 ( 52.38 %)	0	52.38 %

Major shareholders: Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Name	Equities	%	Valuation
Piao Yang Sun 24.16 %	1,538,184,187	24.16 %	12 875 M ¥
Tibet Dazi Dayuan Business Management Co. Ltd. 14.96 %	952,752,304	14.96 %	7 975 M ¥
China State-Owned Assets Supervision & Admn Commission 3.501 %	222,945,466	3.501 %	1 866 M ¥
Qingdao Bosentai Investment Partnership LP 2.856 %	181,826,156	2.856 %	1 522 M ¥
China Asset Management Co., Ltd. 2.433 %	154,937,681	2.433 %	1 297 M ¥
City of Lianyungang 1.756 %	111,815,856	1.756 %	936 M ¥
China Securities Finance Corp. Ltd. 1.498 %	95,399,822	1.498 %	799 M ¥
Huatai-PineBridge Fund Management Co., Ltd. 1.435 %	91,370,886	1.435 %	765 M ¥
Zhong Ou Asset Management Co., Ltd 1.076 %	68,522,864	1.076 %	574 M ¥
ICBC UBS Asset Management Co. Ltd. 0.8538 %	54,363,219	0.8538 %	455 M ¥
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
GIC Pte Ltd. (Investment Management) 23.03 %	59,462,200	23.03 %	521 M ¥
Capital Research & Management Co. (Global Investors) 6.836 %	17,649,400	6.836 %	155 M ¥
Wellington Management Co. LLP 5.64 %	14,563,565	5.64 %	128 M ¥
Boyu Capital Advisory Co. Ltd. 4.971 %	12,834,741	4.971 %	112 M ¥
Invesco Asset Management Ltd. 4.946 %	12,770,573	4.946 %	112 M ¥
HHLR Advisors Ltd. 4.429 %	11,435,800	4.429 %	100 M ¥
UBS Asset Management (Hong Kong) Ltd. 3.891 %	10,047,000	3.891 %	88 M ¥
UBS Asset Management Switzerland AG 2.604 %	6,722,944	2.604 %	59 M ¥
Wellington Management International Ltd. 2.178 %	5,622,544	2.178 %	49 M ¥
JPMorgan Asset Management (Asia Pacific) Ltd. 0.7858 %	2,028,800	0.7858 %	18 M ¥
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Individuals	597.65%
Other	476.42%
Institutional	328.7%
Governments	129.66%

Based on 1000 largest holdings

Geographical origin of shareholders

China	860.82%
Individuals	597.65%
Singapore	23.47%
Hong Kong	20.64%
United States	13.15%
United Kingdom	8.52%
Switzerland	2.74%
Spain	1.69%
Taiwan	0.91%
Luxembourg	0.83%
Italy	0.55%
France	0.38%
Malaysia	0.31%
Denmark	0.2%
Germany	0.16%
Ireland	0.12%
Sweden	0.08%
Netherlands	0.06%
Japan	0.05%
Canada	0.04%
New Zealand	0.02%
Finland	0.02%
Belgium	0.01%
South Africa	0.01%

Based on 1000 largest holdings

Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products: - anti-tumor drugs (No. 1 Chinese); - Anesthetic drugs; - contrast agents: used in medical imaging; - anti-inflammatory drugs; - drugs for the treatment of cardiovascular diseases.

Employees

20,238

Sector

Pharmaceuticals

Calendar

03-25 - Q4 2025 Earnings Release

More about the company